In a report released on December 3, Julian Harrison from BTIG maintained a Buy rating on Rezolute (RZLT – Research Report), with a price target ...

The FDA has granted Orphan Drug designation to ersodetug (RZ358) for the treatment of hypoglycemia due to tumor hyperinsulinism.

Recurrent hypoglycemia increases the risk of severe hypoglycemia and the development ... should be discussed routinely with patients receiving treatment with insulin or sulfonylurea/glinide ...

for the treatment of post-bariatric hypoglycemia (PBH). LUCIDITY is designed to evaluate the FDA-agreed upon primary outcome of reduction in hypoglycemia events and to have similar inclusion and ...

In spite of intravenous treatment with glucose, severe hypoglycemia developed, and the patient died in September, 1961, after a long period of unconsciousness. Permission for autopsy was not granted.

receptor antagonist in development as a potential treatment for PBH. It was designed using the Company’s novel, proprietary PEP™ platform to prevent the occurrence of severe hypoglycemia in ...

U.S. FDA Approves AOP Health’s Rapiblyk™ (landiolol) for Atrial Fibrillation and Atrial Flutter in the Critical Care Setting ...

Hypoglycemia significantly impairs the health, survival, and quality of life in diabetes mellitus. Yet glucagon remains underused, despite being “the only first-line treatment for severe ...

Gvoke®, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia; and Keveyis®, a proven therapy for primary periodic paralysis. Xeris also has a pipeline of development programs ...

We also encourage providers to routinely question their patients about severe hypoglycemia, educate them about hypoglycemia prevention and treatment strategies, and consider modifying treatment ...